摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-甲基喹啉-2-羧酸 | 75434-10-5

中文名称
7-甲基喹啉-2-羧酸
中文别名
——
英文名称
7-methylquinaldic acid
英文别名
7-methylquinoline-2-carboxylic acid;7-methyl-2-quinolinecarboxylic acid;2-carboxy-7-methyl quinoline;7-Methyl-chinolin-2-carbonsaeure
7-甲基喹啉-2-羧酸化学式
CAS
75434-10-5
化学式
C11H9NO2
mdl
MFCD09754110
分子量
187.198
InChiKey
GPSSUARWYWJXCZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    141 °C
  • 沸点:
    361.8±27.0 °C(Predicted)
  • 密度:
    1.285±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    14
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.09
  • 拓扑面积:
    50.2
  • 氢给体数:
    1
  • 氢受体数:
    3

安全信息

  • 危险性防范说明:
    P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
  • 危险性描述:
    H302,H315,H319,H335

SDS

SDS:ad7066296dd0cd8e1589a1b1d45fbefe
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    7-甲基喹啉-2-羧酸 生成 (+/-)-1,2,3,4-tetrahydro-7-methyl-2-quinolinecarboxylic acid hydrochloride
    参考文献:
    名称:
    1-[Acylthio) and
    摘要:
    一系列1-[酰硫基和(巯基)-1-氧代烷基]-1,2,3,4-四氢喹啉-2-羧酸及其盐被用作血管紧张素I转化酶抑制剂。
    公开号:
    US04461896A1
  • 作为产物:
    参考文献:
    名称:
    1-[Acylthio) and
    摘要:
    一系列1-[酰硫基和(巯基)-1-氧代烷基]-1,2,3,4-四氢喹啉-2-羧酸及其盐被用作血管紧张素I转化酶抑制剂。
    公开号:
    US04461896A1
点击查看最新优质反应信息

文献信息

  • Identification and use of protease inhibitors
    申请人:ELI LILLY AND COMPANY
    公开号:EP0652009A1
    公开(公告)日:1995-05-10
    β-amyloid peptide (βAF) production in cell culture and in vivo is inhibited by administering aspartyl protease inhibitors, particularly inhibitors of proteases of cathepsin D. Useful aspartyl protease inhibitors can be selected in a two-step assay, where test compounds are first screened for aspartyl protease inhibition activity in vitro in noncellular assays. Those test compounds which are found to display protease inhibition activity are then tested in cellular assays for βAP production inhibition. Those test compounds which are capable of inhibiting intracellular β-amyloid production may be incorporated in pharmaceutical compositions.
    β-淀粉样蛋白(βAF)在细胞培养和体内的产生受到阻断,通过给予天冬氨酸蛋白酶抑制剂,特别是半胱氨酸蛋白酶D的抑制剂。有用的天冬氨酸蛋白酶抑制剂可以在两步法测定中选择,其中首先在非细胞试验中筛选测试化合物是否具有体外天冬氨酸蛋白酶抑制活性。那些被发现具有蛋白酶抑制活性的测试化合物随后在细胞试验中进行βAP产生抑制的测试。那些能够抑制细胞内β-淀粉样蛋白产生的测试化合物可以被纳入药物组合物中。
  • TRICYCLIC GYRASE INHIBITORS
    申请人:Bensen Daniel
    公开号:US20120238751A1
    公开(公告)日:2012-09-20
    Disclosed herein are compounds having the structure of Formula I and pharmaceutically suitable salts, esters, and prodrugs thereof that are useful as antibacterially effective tricyclic gyrase inhibitors. Related pharmaceutical compositions, uses and methods of making the compounds are also contemplated.
    本文披露了具有式I结构的化合物,以及作为抗菌有效的三环酶抑制剂的药用盐、酯和前药,相关的药物组合物、用途和制备该化合物的方法也在考虑之中。
  • BICYCLIC AROMATIC CARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS
    申请人:Incyte Corporation
    公开号:US20160009714A1
    公开(公告)日:2016-01-14
    The present disclosure describes bicyclic aromatic carboxamide derivatives, as well as their compositions and methods of use. The compounds inhibit the activity of the Pim kinases, and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancer and other diseases.
    本公开描述了双环芳香羧酰胺衍生物,以及它们的组合物和使用方法。这些化合物抑制Pim激酶的活性,并可用于治疗与Pim激酶活性相关的疾病,例如癌症和其他疾病。
  • Saframycins, analogues and uses thereof
    申请人:——
    公开号:US20040204419A1
    公开(公告)日:2004-10-14
    In recognition of the need to develop novel therapeutic agents and efficient methods for the synthesis thereof, the present invention provides novel compounds of general formula (I), and methods for the synthesis thereof. 1 In another aspect, the present invention provides pharmaceutical compositions comprising a compound of formula (I) and a pharmaceutically acceptable carrier. In yet another aspect, the present invention provides methods for treating cancer comprising administering a therapeutically effective amount of a compound of formula (I) to a subject in need thereof.
    为了开发新型治疗剂和高效合成方法,本发明提供了一般式(I)的新化合物及其合成方法。另外,本发明提供了包含式(I)化合物和药用载体的制药组合物。还提供了用于治疗癌症的方法,包括向需要治疗的对象施用一定剂量的式(I)化合物。
  • Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds
    申请人:Arimilli N. Murty
    公开号:US20070010489A1
    公开(公告)日:2007-01-11
    Phosphonate substituted compounds with HIV protease inhibitory properties having use as therapeutics and for other industrial purposes are disclosed. The compositions inhibit 5 HIV protease activity and/or are useful therapeutically for the treatment of AIDS and other antiviral infections, as well as in assays for the detection of HIV protease.
    本发明揭示了具有HIV蛋白酶抑制剂性质的膦酸酯取代化合物,其具有作为治疗剂和其他工业用途的用途。该组合物抑制5型HIV蛋白酶活性和/或在治疗艾滋病和其他抗病毒感染方面具有治疗作用,以及在检测HIV蛋白酶方面的检测中有用。
查看更多